CervoMed is trading 5.14% higher at $1.84 in pre-market on October 30, alongside a 1.32% pre-market gain in healthcare; the available company news does not clearly explain the move. - Shares closed at $1.75 on October 29. - CervoMed’s October 29 research announcement reported supportive findings, but its Phase 2b trial did not confirm the primary outcome in the overall population.